Ocugen, Inc. has entered into an Exclusive License Agreement with Celairis Therapeutics Holdings Pty Ltd, granting Celairis exclusive rights to commercialize the OCU400 product in select countries across Asia and Oceania. The agreement includes a potential $6.1 million in fees and milestone payments, as well as royalties on net sales. The partnership aims to leverage Celairis's regulatory expertise to facilitate product approval and commercialization in the defined territory.
Company Information
Company
Ocugen
Location
11 Great Valley Parkway
Malvern, Pennsylvania, United States
About
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patients’ lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs.
MalvernBiotechnologyHealthcareHealth CareTherapeutics